Fiche publication
Date publication
décembre 2025
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice
Tous les auteurs :
Ródon J, Arkenau HT, Funchain P, Hervieu A, Anthony K, Chawla SP, Laetsch TW, Murciano-Goroff YR, Singer CF, He Y, Mina M, Wacheck V, Delaloge S
Lien Pubmed
Résumé
Protein kinase B (AKT)-directed therapies offer promise for patients with cancers harboring germline and somatic phosphatase and tensin homolog (PTEN) mutations. TAS-117 is an oral, selective, non-adenosine triphosphate-competitive allosteric AKT inhibitor that showed encouraging antitumor activity in a phase I study. This phase II study aimed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAS-117 in patients with advanced/metastatic solid tumors, including those harboring germline PTEN-inactivating mutations (EudraCT: 2020-004770-22).
Mots clés
AKT inhibitor, TAS-117, advanced solid tumor, germline PTEN mutation, phase II study
Référence
ESMO Open. 2025 12 30;11(1):105932
